Nuvation Bio Inc.
NUVB · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.97 | -0.45 | -0.42 | 0.00 |
| FCF Yield | -4.18% | -7.28% | -7.16% | -5.16% |
| EV / EBITDA | -22.38 | -8.14 | -10.58 | -17.69 |
| Quality | ||||
| ROIC | -10.43% | -10.81% | -13.19% | -11.00% |
| Gross Margin | 74.47% | 46.70% | 32.10% | 26.18% |
| Cash Conversion Ratio | 0.95 | 0.82 | 0.80 | 0.94 |
| Growth | ||||
| Revenue 3-Year CAGR | 2,990,537.48% | 2,430,243.90% | 2,220,978.39% | 1,989,260.16% |
| Free Cash Flow Growth | -9.39% | -13.26% | 7.76% | -48.21% |
| Safety | ||||
| Net Debt / EBITDA | 0.76 | 3.27 | 0.69 | 0.55 |
| Interest Coverage | -112.64 | -151.04 | -1,092.67 | -606.09 |
| Efficiency | ||||
| Inventory Turnover | 0.59 | 4.67 | 149.57 | 0.00 |
| Cash Conversion Cycle | -164.32 | -639.65 | -292.88 | 121.23 |